EPIRUS Biopharmaceuticals Appoints Industry Veteran Vincent E. Aurentz as Chief Business Officer
10 Noviembre 2015 - 7:00AM
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical
company focused on the global development and commercialization of
biosimilar monoclonal antibodies (mAbs), today announced that
Vincent E. Aurentz has joined the Company as Chief Business
Officer.
“We are pleased to welcome Vince to the EPIRUS
team as we continue our mission to build a sustainable, profitable
biosimilar business,” said Amit Munshi, President and Chief
Executive Officer, EPIRUS Biopharmaceuticals. “We are confident his
more than 25 years of diverse experience in the life sciences
industry, including R&D and business development, will
contribute greatly to EPIRUS moving forward as we develop and
commercialize biosimilars in global markets.”
“As the biosimilars sector continues to
establish itself in an industry that is undergoing measurable
changes, it is an exciting time to join the executive team at
EPIRUS,” said Aurentz. “Companies focused on biosimilars are poised
to have a major impact to address the challenges facing our global
healthcare system, and I look forward to being part of EPIRUS to
expand the access and availability of biosimilars and improve the
delivery of healthcare.”
Aurentz most recently served as the President of
HemoShear Therapeutics, where he oversaw the scientific and
business development efforts including collaborations with global
organizations such as Pfizer, Eli Lilly, Janssen R&D and
Children’s National Health System. Prior to joining HemoShear
Therapeutics, Mr. Aurentz was Executive Vice President and member
of the Executive Management Board at Merck KGaA (Merck Serono)
where he directed R&D programs, portfolio strategy and headed
all deal activity and venture investments. He is a former Executive
Vice President at Quintiles, Co-founder and Managing Director of a
venture capital and advisory business and started his career at
Andersen Consulting (now Accenture).
About EPIRUS
BiopharmaceuticalsEPIRUS Biopharmaceuticals (Nasdaq:EPRS)
is a biopharmaceutical company focused on the global development
and commercialization of biosimilar monoclonal antibodies (mAbs).
EPIRUS’ goal is to improve global patient access to important,
cost-effective medicines. EPIRUS' current pipeline of
biosimilar product candidates includes: BOW015 (infliximab,
reference biologic Remicade®); BOW050 (adalimumab, reference
biologic Humira®); BOW070 (tocilizumab, reference biologic
Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090
(ustekinumab, reference biologic STELARA®); and BOW100 (golimumab,
reference biologic SIMPONI®)[i]. The reference products for these
candidates together generated approximately $29.2 billion in global
sales for 2014, according to EvaluatePharma®. EPIRUS has
established multiple partnerships to support its regulatory and
commercialization efforts in global markets. For more information
visit EPIRUS’ website at www.epirusbiopharma.com.
_____________________________
i Remicade is a registered trademark of Johnson and Johnson
(www.jnj.com); Humira is a registered trademark of AbbVie
(www.abbvie.com); Actemra is a registered trademark of Chugai
Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group
(www.gene.com); Stelara is owned and marketed by Centocor Ortho
Biotech Inc, a wholly owned subsidiary of Johnson and Johnson
(www.jnj.com); Simponi is marketed by Janssen Biotech Inc
(www.janssenbiotech.com); Soliris is a registered trademark of
Alexion Pharmaceuticals, Inc. (www.alxn.com)
Contact Information:
For media inquiries:
Mike Devine, FleishmanHillard
+1-212-453-2324
michael.devine@fleishman.com
For investor inquiries:
Tom Shea, EPIRUS Biopharmaceuticals
+1-617-600-3471
tshea@epirusbiopharma.com
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfica de Acción Histórica
De May 2023 a May 2024